Pathway Analysis for Design of Promiscuous Drugs and Selective Drug Mixtures
Authors: Sivachenko, Andrey1; Kalinin, Andrey1; Yuryev, Anton1
Source: Current Drug Discovery Technologies, Volume 3, Number 4, December 2006 , pp. 269-277(9)
Publisher: Bentham Science Publishers
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
The decrease in the drug approval rate by the FDA and the recent failure of some blockbuster drugs has prompted a re-examination of the focus of the pharmaceutical industry on increasing drug selectivity. As a result, it has been proposed that the most efficient cure is in developing promiscuous drugs and selective drug mixtures. Rational design of drug mixtures has been nearly impossible due to the lack of information about in vivo cell regulation, mechanisms of pathway activation, and interactions between different pathways in vivo. We review the current state of the art for rational design of combination therapy and argue that the current industry-wide development of the infrastructure for pathway analysis provides unprecedented opportunity for the rational design of multicomponent and multifunctional drugs. We propose several ways how to use pathway analysis to rationally combine known drugs for either synergizing their efficacy or suppressing individual side effects.Keywords: tyrosine kinase inhibitor; Pathway analysis; cyclooxegenases; EGF receptor; VEGF
Document Type: Research article
DOI: 10.2174/157016306780368117
Affiliations: 1: Application Science Dept.Ariadne Genomics Inc. 9430 Key West avenue, Suite 113, Rockville, MD 20850, USA.
Key:
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help